GlassScriptPhysician profile
Christen Ground
NPI 1689021842
$1,229.76
in general payments reported to CMS, 2019-2025
14 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.55 · 2021: $20.24 · 2022: $97.02 · 2023: $357 · 2024: $398 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.50 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.08 | 2023-2025 | |
| Novo Nordisk INC | $163.77 | 2022-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $130.56 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $130.55 | 2021-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $107.29 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $102.96 | 2022-2024 | Jardiance, Zepbound, Trulicity |
| Amgen INC. | $35.65 | 2023-2024 | Repatha, Otezla |
| Aimmune Therapeutics, INC. | $28.52 | 2025 | Zenpep |
| Myriad Women'S Health, INC. | $26.65 | 2023 | Myrisk |
| Mylan Specialty L.P. | $21.27 | 2024 | Yupelri |
| Viatris Specialty LLC | $20.09 | 2025 | Yupelri |
| Pfizer INC. | $18.90 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.92 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christen Ground listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.